Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Release FY 2022 Financial Report, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development and manufacturing of rare cannabinoids, will be releasing its financial report for fiscal year 2022, the period ended June 30, 2022, later this month. The company has announced that it will release the financial report, along with business highlights, on Sept. 23, 2022. In addition, the company has announced a conference call and webcast to be held the same day at 1 p.m. ET. Those interested in listening in on the conference call can register for the call; they will then receive information about how to dial in to the call.

To register for the event, visit https://ibn.fm/DD1MI

To view the full press release, visit https://ibn.fm/XGfu7

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in InMed Pharmaceuticals Inc. INM. Bookmark the permalink.

Comments are closed.